Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Nivolumab (Opdivo) for Hodgkin lymphoma in brentuximab naïve patients – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Hodgkin lymphoma is a cancer of the lymphatic system – part of the body's immune system. In Hodgkin lymphoma, blood cells called lymphocytes become abnormal, increase in number and collect in the lymph nodes (glands) and other organs.
Nivolumab is a new antibody drug for the treatment of Hodgkin lymphoma, and is delivered straight into the bloodstream via a drip. Some studies have suggested nivolumab may be helpful for people whose first treatment has failed and whose disease has spread despite treatment with a bone marrow transplant. Nivolumab is currently being studied to see how well it works and whether it is safe to use in people with Hodgkin lymphoma.
If nivolumab is licensed for use in the UK, it could be a new treatment option for this patient group that may improve survival and quality of life when current treatments have not worked. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Hodgkin Disease; Humans; Immunoconjugates Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000401 Date abstract record published 04/03/2016 |